Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BV-T829
- Development stage
- Preclinical
- Lead developer
- BioViva
- Modality
- Gene Therapies
- Administration
- Intravenous, Intramuscular
01
Overview
BV-T829 is a preclinical gene therapy candidate developed by BioViva, a biotechnology company focused on longevity and regenerative medicine. The candidate is designed to deliver the gene for telomerase reverse transcriptase (TERT) using a viral vector, such as an adeno-associated virus (AAV) or cytomegalovirus (CMV). The primary objective of BV-T829 is to combat cellular senescence by extending telomeres, which naturally shorten as cells divide, thereby potentially treating a variety of age-related conditions and improving overall healthspan. The program is part of BioViva's early-stage portfolio aimed at cellular rejuvenation and regenerative medicine.
02
Targets
TERT (Telomerase)
Beyond the preview
Go deeper on BV-T829.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BV-T829.